The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
TIBSOVO (Servier Laboratories (Aust) Pty Ltd)
Product name
TIBSOVO
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
ivosidenib
Registration type
NCE/NBE
Indication
TIBSOVO is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation after at least one prior line of systemic therapy.